Anti‐HER2 therapy is important for PABC, as patients often present with HER2 overexpression.28 Trastuzumab is approved for the treatment of HER2‐positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings. The gene discussed is ERBB2; the disease is breast carcinoma.